Catalyst

Slingshot members are tracking this event:

European Ad Comm Recommends for Approval Amgen's (AMGN) Parsabiv in Treatment of Secondary Hyperthyroidism

Source Link:
http://www.amgen.com/media/news-releases/2016/09/amgen-receives-positive-chmp-opinion-for-parsabiv-etelcalcetide-for-the-treatment-of-secondary-hyperparathyroidism-in-adult-patients-with-chronic-kidney-disease-on-hemodialysis/

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AMGN
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Sep 16, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Secondary Hyperthyroidism, Chmp, European Medicines Agency, Parsabiv
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.